Abstract 116P
Background
About 80% of all lung cancers are non-small cell lung cancer (NSCLC). The early stages are asymptomatic which lead to a late diagnosis. Surgery is the preferred option for stages I and II but the best treatment modality for stages III and IV are chemotherapy and radiotherapy. However, some studies have shown that NSCLC is chemotherapy resistant, which leaves some debates. So, this study aimed to assess the outcome of chemotherapy in stage III cancers.
Methods
Data of 2368 patients was extracted from Surveillance, Epidemiological, and End Results (SEER) database. All of them had stage III non-small cell lung cancer diagnosed from 2000–2019. The classification of stage III was according to eighth edition of AJCC. We divided the patients into four groups; groups who received chemotherapy and groups who had no systemic therapy for stages IIIA and IIIB each. For each group, we calculated relative 5-year survival, and using SPSS 25, we performed Kaplan-Meier curve and log rank test for survival analysis.
Results
The 5-year relative survival for the groups who received chemotherapy for stages IIIA and IIIB and the groups who had no systemic therapy for stages IIIA and IIIB were (23.8%, 18.1%, 7.6%, 6.6% respectively; P < 0.001). The overall survival of sex for stage III was 9.2% for males, and 10.7% for females (P < 0.02). Performing Cox regression model revealed, sex was associated with poor survival outcomes as IIIA (P < 0.001, HR: 1.12, 95%CI: 0.995–1.261) and IIIB (P < 0.001, HR: 1.1, 95%CI: 0.964–1.234,).
Conclusions
Non-small cell lung cancer patients who received chemotherapy showed threefold higher 5-year relative survival compared to the groups who had no systemic therapy. These results also showed that sex is associated with poor survival outcome. So, we recommend chemotherapy to be the first line of treatment for stages IIIA and IIIB for better survival outcome.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.